Labcorp to buy BioReference assets for up to $872M

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 15 Oct, 15:18 UTC

Labcorp will pick up specialty testing in women’s health as well as a blood test that assesses the likelihood of finding aggressive prostate cancer before a biopsy decision.

science

Sources

• T2Labcorp to buy BioReference assets for up to $872MBioPharma Dive / Healthcare Dive / MedTech Dive15 Oct, 15:18